We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00743496
First Posted: August 28, 2008
Last Update Posted: August 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Evan T.J. Dunbar Neuroblastoma Foundation
Duke University
University of Wisconsin, Madison
University Children’s Hospital Tuebingen
Children's Hospital Los Angeles
Information provided by (Responsible Party):
St. Jude Children's Research Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 18, 2014
  Primary Completion Date: April 1, 2014 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):